mRESVIA® (Respiratory Syncytial Virus Vaccine)

Exceptional convenience

Administration with a pre-filled syringe has its benefits.⁴

Discover the mRESVIA difference

Proven efficacy¹

See the results of the clinical trial.¹

Explore the endpoints

A demonstrated safety profile¹

Safety was tested in a large and diverse clinical trial.¹

See safety data

Talking to your adult patients about RSV

Patients aged 60 or older may not realize the risks associated with RSV. You can help them understand what's at stake.

There is no treatment for an RSV infection beyond supportive care^5,6
An effective way for older adults—especially those with underlying health issues—to avoid getting sick with RSV is to get vaccinated⁷

Start the conversation with the Patient Discussion Guide.

Download now

CDC Recommended⁸

To protect against RSV, the CDC recommends vaccinating all adult patients who are:

Aged 60 or older with increased risk of severe RSV disease⁸
Aged 75 years or older⁸

Talk to your older adult patients to determine if mRESVIA is right for them.

Indication and Important Safety Information

Indication

mRESVIA® (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.

Important Safety Information

Contraindications

Do not administer mRESVIA to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of mRESVIA.

Warnings and Precautions

Management of Acute Allergic Reactions: Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of mRESVIA.
Syncope: Syncope (fainting) may occur in association with administration of injectable vaccines, including mRESVIA. Procedures should be in place to avoid injury from fainting.
Altered Immunocompetence: Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to mRESVIA.

Adverse Reactions

In a clinical trial, the most commonly reported (≥10%) adverse reactions were injection-site pain (55.9%), fatigue (30.8%), headache (26.7%), myalgia (25.6%), arthralgia (21.7%), axillary (underarm) swelling or tenderness (15.2%) and chills (11.6%).

To report suspected adverse reactions, contact ModernaTX, Inc. at 1-866-663-3762 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please click for mRESVIA Full Prescribing Information.

References

mRESVIA Prescribing Information. ModernaTX, Inc.
AREXVY Prescribing Information. GlaxoSmithKline Biologics SA.
ABRYSVO Product Information. Pfizer Inc.
Icardi G, Orsi A, Vitali Rosati G, Tognetto A, Checcucci Lisi G, Parisi S. Preferences of healthcare professionals regarding hexavalent pediatric vaccines in Italy: a survey of attitudes and expectations. J Prev Med Hyg. 2020;61(3):E424-E444. doi:10.15167/2421-4248/jpmh2020.61.3.1535
Malik S, Ahmad T, Muhammad K, Waheed Y. Respiratory syncytial virus infection: treatments and clinical management. Vaccines (Basel). 2023;11(2):491. doi:10.3390/vaccines11020491
Gatt D, Martin I, AlFouzan R, Moraes TJ. Prevention and treatment strategies for respiratory syncytial virus (RSV). Pathogens. 2023;12(2):154. doi:10.3390/pathogens12020154
Centers for Disease Control and Prevention. RSV in older adults and adults with chronic medical conditions. Updated June 5, 2024. Accessed June 25, 2024. https://www.cdc.gov/rsv/older-adults/?CDC_AAref_Val=https://www.cdc.gov/rsv/high-risk/older-adults.html
Centers for Disease Control and Prevention. CDC updates RSV vaccination recommendation for adults. Updated June 26, 2024. Accessed September 5, 2024. https://www.cdc.gov/media/releases/2024/s-0626-vaccination-adults.html

For Colorado and Connecticut price disclosure, please visit https://modernadirect.com/wac-disclosure

Stay up to date

Receive the latest information about mRESVIA and all the products in the Moderna pipeline.

By submitting your information, you agree to Moderna's Terms and Conditions. You also acknowledge that your information will be processed in accordance with Moderna's Privacy Statement. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.